Collection of Samples USOPTIVAL Study

Status Recruiting

Clinical Trial Summary

A prospective multi-center observational study. The study will enroll eligible subjects from the United States to optimize the biomarker panel and evaluate the performance of a cfDNA marker panel selected by the Sponsor for CRC and advanced adenoma detection.

Clinical Trial Description

This study is designed to prospectively collect blood samples and clinical data from subjects that have a suspected advanced adenoma or have been newly diagnosed with CRC scheduled for resection surgery, as well as subjects who are at average-risk of colorectal cancer and who are scheduled for routine colonoscopy examination. Subjects interested in participation and who meet inclusion criteria and provide written informed consent will be enrolled in the study. By accepting participation in the study, subjects will consent to provide up to 40 ml of blood at the study visit. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04792684
Study type	Observational
Source	Universal Diagnostics
Contact	Alvaro Leiva
Phone	(+34) 674 94 55 33
Email	aleiva@universaldx.com
Status	Recruiting
Phase
Start date	December 30, 2020
Completion date	June 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06040541` - Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors	Phase 1
Completed	`NCT01450319` - A Phase 2 Clinical Study of Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype	Phase 2
Recruiting	`NCT05462717` - Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors	Phase 1
Recruiting	`NCT04083599` - GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors	Phase 1/Phase 2
Completed	`NCT02903914` - Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors	Phase 1/Phase 2
Terminated	`NCT03253185` - A Study of SC-007 in Subjects With Advanced Cancer	Phase 1
Completed	`NCT00851045` - Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer	Phase 2
Recruiting	`NCT06026410` - KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors	Phase 1
Recruiting	`NCT04622423` - Advanced Therapies for Liver Metastases
Active, not recruiting	`NCT02955940` - An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib	Phase 2
Completed	`NCT02327078` - A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)	Phase 1/Phase 2
Completed	`NCT03314935` - A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05379985` - Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS	Phase 1
Recruiting	`NCT05648955` - Effect of an Oral Nutritional Supplement on Muscle Mass During Anticancer Treatment	Early Phase 1
Completed	`NCT00165854` - Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer	Phase 2
Recruiting	`NCT05706129` - A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT02646748` - Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors	Phase 1
Not yet recruiting	`NCT02005913` - A Novel Patent Platform of Detection of Circulating Tumor Cells to Early Detect Colorectal Cancer Recurrence	N/A
Recruiting	`NCT04256707` - Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment	Phase 1/Phase 2
Completed	`NCT00483080` - Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC)	Phase 2